{"nctId":"NCT00948896","briefTitle":"Chemopreventive Therapy for Malaria in Ugandan Children","startDateStruct":{"date":"2010-06"},"conditions":["Malaria"],"count":600,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: trimethoprim-sulfamethoxazole (TS; TMP/SMX)"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: sulfadoxine-pyrimethamine (SP)"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Drug: dihydroartemisinin-piperaquine (DP)"]},{"label":"4","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"trimethoprim-sulfamethoxazole (TS; TMP/SMX)","otherNames":[]},{"name":"sulfadoxine-pyrimethamine (SP)","otherNames":[]},{"name":"dihydroartemisinin-piperaquine (DP)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age 4 -5 months\n2. Confirmed HIV status of biological mother\n3. Negative HIV DNA PCR test at time of enrollment for infants born to HIV-infected mothers\n4. Infants born to HIV-infected mothers must be breastfeeding\n5. Residency within 30km of the study clinic\n6. Agreement to come to the study clinic for any febrile episode or other illness and avoid medications given outside the study protocol\n7. Provision of informed consent by parent/guardian\n\nExclusion Criteria:\n\n1. History of allergy or sensitivity to TS, SP, or DP\n2. Active medical problem requiring in-patient evaluation at the time of screening\n3. Intention of moving more that 30km from the study clinic during the follow-up period\n4. Chronic medical condition (i.e. malignancy) requiring frequent medical attention\n5. Living in the same household as a previously enrolled study participant\n6. QTc interval \\> 450 msec\n7. Other clinically significant ECG abnormalities such as arrhythmia, ischemia, or evidence of heart failure\n8. Family history of Long QT syndrome\n9. Current use of drugs that prolong the QT interval","healthyVolunteers":true,"sex":"ALL","minimumAge":"4 Months","maximumAge":"5 Months","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Incidence of Any Adverse Events Defined as Severity Grade 3-4 That Are Possibly, Probably, or Definitely Related to Study Drugs","description":"NIH Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events published December, 2004","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.159","spread":null},{"groupId":"OG001","value":"1.415","spread":null},{"groupId":"OG002","value":"0.914","spread":null},{"groupId":"OG003","value":"0.611","spread":null},{"groupId":"OG004","value":"1.214","spread":null},{"groupId":"OG005","value":"1.478","spread":null},{"groupId":"OG006","value":"0.659","spread":null},{"groupId":"OG007","value":"0.678","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"0.056","spread":null},{"groupId":"OG002","value":"0.054","spread":null},{"groupId":"OG003","value":"0.021","spread":null},{"groupId":"OG004","value":"NA","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0.062","spread":null},{"groupId":"OG007","value":"0.097","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.178","spread":null},{"groupId":"OG001","value":"0.364","spread":null},{"groupId":"OG002","value":"0.196","spread":null},{"groupId":"OG003","value":"0.091","spread":null},{"groupId":"OG004","value":"0.411","spread":null},{"groupId":"OG005","value":"0.453","spread":null},{"groupId":"OG006","value":"0.330","spread":null},{"groupId":"OG007","value":"0.194","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.542","spread":null},{"groupId":"OG001","value":"0.546","spread":null},{"groupId":"OG002","value":"0.393","spread":null},{"groupId":"OG003","value":"0.323","spread":null},{"groupId":"OG004","value":"0.431","spread":null},{"groupId":"OG005","value":"0.532","spread":null},{"groupId":"OG006","value":"0.206","spread":null},{"groupId":"OG007","value":"0.174","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.384","spread":null},{"groupId":"OG001","value":"0.602","spread":null},{"groupId":"OG002","value":"0.318","spread":null},{"groupId":"OG003","value":"0.168","spread":null},{"groupId":"OG004","value":"0.705","spread":null},{"groupId":"OG005","value":"0.631","spread":null},{"groupId":"OG006","value":"0.206","spread":null},{"groupId":"OG007","value":"0.291","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.123","spread":null},{"groupId":"OG001","value":"0.119","spread":null},{"groupId":"OG002","value":"0.061","spread":null},{"groupId":"OG003","value":"0.035","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0.118","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0.058","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.048","spread":null},{"groupId":"OG001","value":"0.056","spread":null},{"groupId":"OG002","value":"0.041","spread":null},{"groupId":"OG003","value":"0.021","spread":null},{"groupId":"OG004","value":"0.039","spread":null},{"groupId":"OG005","value":"0.020","spread":null},{"groupId":"OG006","value":"0.041","spread":null},{"groupId":"OG007","value":"0.039","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.027","spread":null},{"groupId":"OG001","value":"0.028","spread":null},{"groupId":"OG002","value":"0.027","spread":null},{"groupId":"OG003","value":"0.021","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.021","spread":null},{"groupId":"OG001","value":"0.042","spread":null},{"groupId":"OG002","value":"0.014","spread":null},{"groupId":"OG003","value":"0.007","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0.020","spread":null},{"groupId":"OG005","value":"0.020","spread":null},{"groupId":"OG006","value":"0.021","spread":null},{"groupId":"OG007","value":"0.039","spread":null}]}]}]},{"type":"SECONDARY","title":"Rebound Incidence of Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.85","spread":null},{"groupId":"OG001","value":"11.98","spread":null},{"groupId":"OG002","value":"10.90","spread":null},{"groupId":"OG003","value":"10.77","spread":null},{"groupId":"OG004","value":"9.08","spread":null},{"groupId":"OG005","value":"6.75","spread":null},{"groupId":"OG006","value":"8.13","spread":null},{"groupId":"OG007","value":"6.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.046","spread":null},{"groupId":"OG001","value":"0.132","spread":null},{"groupId":"OG002","value":"0.046","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0.161","spread":null},{"groupId":"OG005","value":"0.147","spread":null},{"groupId":"OG006","value":"0.116","spread":null},{"groupId":"OG007","value":"0.044","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.046","spread":null},{"groupId":"OG001","value":"0.452","spread":null},{"groupId":"OG002","value":"0.091","spread":null},{"groupId":"OG003","value":"0.023","spread":null},{"groupId":"OG004","value":"0.459","spread":null},{"groupId":"OG005","value":"0.318","spread":null},{"groupId":"OG006","value":"0.186","spread":null},{"groupId":"OG007","value":"0.089","spread":null}]}]}]},{"type":"PRIMARY","title":"Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants","description":"The incidence of malaria, defined as the number of incident episodes per time at risk, during the period the intervention was given (6-24 mo of age). Treatments within 14d of a prior episode were not considered incident events. Time at risk was from the day following the initiation of study drugs to the last day of observation, minus 14 d after each treatment for malaria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.95","spread":null},{"groupId":"OG001","value":"6.73","spread":null},{"groupId":"OG002","value":"5.21","spread":null},{"groupId":"OG003","value":"3.02","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.41","spread":null},{"groupId":"OG001","value":"5.51","spread":null},{"groupId":"OG002","value":"3.27","spread":null},{"groupId":"OG003","value":"1.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.24","spread":null},{"groupId":"OG001","value":"7.41","spread":null},{"groupId":"OG002","value":"6.32","spread":null},{"groupId":"OG003","value":"3.88","spread":null}]}]}]},{"type":"PRIMARY","title":"Incident Malaria Cases Per Person Year at Risk in HIV-exposed Participants","description":"The primary outcome was the incidence of malaria, defined as the number of incident episodes per time at risk, during the period the intervention was given. Treatments within 14 days of a prior episode were not considered incident events. Time at risk was from the day following the initiation of study drugs to the last day of observation, minus 14 days after each treatment for malaria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.28","spread":null},{"groupId":"OG001","value":"4.50","spread":null},{"groupId":"OG002","value":"2.86","spread":null},{"groupId":"OG003","value":"1.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.42","spread":null},{"groupId":"OG001","value":"3.72","spread":null},{"groupId":"OG002","value":"1.70","spread":null},{"groupId":"OG003","value":"0.90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.04","spread":null},{"groupId":"OG001","value":"5.22","spread":null},{"groupId":"OG002","value":"3.79","spread":null},{"groupId":"OG003","value":"2.67","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":98},"commonTop":["Elevated temperature","Anemia","Thrombocytopenia","Elevated AST (SGOT)","Elevated ALT (SGPT)"]}}}